Full Press Release Details
Signs a Transaction Agreement To Acquire AiPharma, Rights Holder Of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of
Over 1.5 Million Covid-19 Patients Outside the U.S. and Canada
clinical trial of Avigan/Reeqonus for treatment of COVID-19 completed enrollment of more than 1,200 patients in the U.S., Mexico and
Brazil with topline results expected in less than 60 days
VA - October 5, 2021 - Aditxt, Inc. ("Aditxt") (Nasdaq: ADTX), a biotech innovation company with a mission
to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement
by the end of November 2021 to acquire a subsidiary ("AiPharma") of AiPharma Global Holdings LLC ("AiPharma Global")
which is to own all of the assets of AiPharma Global, a company focused on discovering, developing and commercializing antiviral therapies
across a broad spectrum of infectious diseases.
Global is a biopharmaceutical company that holds directly, or through its affiliates worldwide (excluding Japan), exclusive rights to
Avigan/Reeqonus/Qifenda and all formulations of favipiravir, a broad spectrum oral antiviral drug that targets COVID-19 and other infectious
diseases. The binding agreement follows Aditxt's prior announcement on August 25, 2021 to acquire the company and Aditxt's
funding of a bridge loan to AiPharma Global in the amount of $6.5 million.
acquisition, if completed, will form a business segment for Aditxt that is focused on the monitoring and treatment of infectious diseases.
Key terms of the agreement include: an increase in the amount of permitted borrowings under the secured loan from Aditxt to AiPharma
Global by $8.5 million resulting in total availability of $15 million, as well as Aditxt issuing such number of shares of common stock
that yields 65% of the number of Aditxt's outstanding shares calculated as of September 30, 2021 to be issued only upon closing
acquisition is subject to confirmatory due diligence, entry into a definitive agreement based on agreed terms and other closing conditions,
including regulatory, board, shareholder, and Nasdaq approvals. There is no assurance that the aforementioned approvals will be granted.
acquisition highlights:
completion of this acquisition would accelerate our commercialization plans in the infectious disease space and would uniquely position
Aditxt by combining our commercialized AditxtScoreTM for COVID-19 test with an at-home treatment for the disease. While initially
targeting COVID-19, our combined clinical and commercial platform would potentially address unmet needs in other viral indications,"
stated Aditxt Co-Founder and CEO Amro Albanna. "We look forward to partnering with the team at AiPharma and its consortium members."
Alessandro Gadotti, CEO of AiPharma Group commented, "We believe that the combination of Aditxt and AiPharma is uniquely positioned
to address the key topics of the COVID-19 pandemic, starting from monitoring of immune status and outpatient treatment for the illness.
In excess of 1.5 million patients have been treated with our antiviral tablets. The strength of oral antiviral treatments such as Avigan/Reeqonus
in real terms is that they fight COVID-19 in the community and not in hospitals - which can significantly reduce pressures on healthcare
systems. Our joint product portfolio puts us on the front line in the fight against COVID-19 and future pandemic preparedness."
Avigan/ Reeqonus / Qifenda (favipiravir)
/Reeqonus / Qifenda (favipiravir) is a broad-spectrum antiviral in oral tablet form developed by FUJIFILM Toyama Chemical Co., Ltd.
(FFTC). Following promising clinical studies, Russia, Thailand, Indonesia, India and Malaysia approved favipiravir-based antiviral
medications for the emergency treatment of COVID-19.
clinical trials for favipiravir in COVID-19 are ongoing in the United States, China, India, and the United Kingdom. Unlike most other
interventions that researchers are evaluating in the COVID-19 indication, favipiravir has already been thoroughly studied in human trials
outside of North America and has a known safety profile, with over 3,000 subjects receiving at least one dose of the drug in controlled
clinical trials, and more than 30,000 people having received Avigan in Observational Studies. The safety profile has been further confirmed
by the hundreds of thousands of patients that have received favipiravir during the COVID-19 pandemics in the authorized countries. Favipiravir's
oral tablet form may also provide advantages in the community setting over other COVID-19 interventions, which often require injection
or intravenous administration.
is approved for manufacture and sale in Japan as an anti-influenza virus drug and as a treatment and stockpile countermeasure for pandemic
influenza. The Japanese government has contracted with Fujifilm to purchase a stockpile of over 65 million tablets.
is developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's
immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune
reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with
an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit:
Global is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies to address the unmet medical
needs of patients with life-threatening viral diseases. Leveraging the Company's deep understanding of antiviral drug development,
nucleotide chemistry, biology, biochemistry, and virology, AiPharma Global has built a nucleotide prodrug platform to develop novel product
candidates to treat single-stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently,
AiPharma Global is focused on the clinical and commercial development of orally available, potent, and selective nucleotide prodrugs
for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). AiPharma Global also holds exclusive
commercial rights for Avigan in Russia and China.
more information, please visit www.aipharmalab.com.
statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward
looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations
concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual
property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the
Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry
in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees
of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the
Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the
Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,
future events or otherwise.
and Investor Relations Contact: